Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics

作者：Xiaojun Feng, Antoni Sureda, Samineh Jafari, Zahra Memariani, Devesh Tewari, Giuseppe Annunziata, Luigi Barrea, Sherif T. S. Hassan, Karel Šmejkal, Milan Malaník, Alice Sychrová, Davide Barreca, Lovro Žiberna, Mohamad Fawzi Mahomoodally, Gökhan Zengin, Suowen Xu, Seyed Mohammad Nabavi, Ai-Zong Shen · 发表于：Theranostics · 年份：2019 · DOI：10.7150/thno.30787 · 被引用次数：461 · 研究领域：Berberine and alkaloids research、Diet, Metabolism, and Disease、Plant-based Medicinal Research

Cardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide, underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years. Recently, BBR has attracted much interest for its pharmacological actions in treating and/or managing CVMD. Recent discoveries of basic, translational and clinical studies have identified many novel molecular targets of BBR (such as AMPK, SIRT1, LDLR, PCSK9, and PTP1B) and provided novel evidences supporting the promising therapeutic potential of BBR to combat CVMD. Thus, this review provides a timely overview of the pharmacological properties and therapeutic application of BBR in CVMD, and underlines recent pharmacological advances which validate BBR as a promising lead drug against CVMD.